Analysis of 103 Patients with Unknown Primary Carcinoma: Retrospective Study.
- Author:
Jae Jin LEE
1
;
Si Young KIM
;
Kyung Sam CHO
;
Juhie LEE
;
Hwi Joong YOON
Author Information
1. Department of Internal Medicine, Kyunghee University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Unknown primary carcinoma;
Prognosis;
Survival rate;
Chemotherapy
- MeSH:
Adenocarcinoma;
Breast;
Carcinoma, Squamous Cell;
Drug Therapy;
Female;
Humans;
Lung;
Multivariate Analysis;
Ovary;
Prognosis;
Quality of Life;
Retrospective Studies*;
Survival Rate
- From:Journal of the Korean Cancer Association
2001;33(1):1-8
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Unknown primary carcinoma takes up approximately 0.5-10% of the oncology patients evaluated, and the patients have poor survival of between 3 to 11 months. Despite the short survival, certain clinically defined subsets of patients were reported to have a better prognosis. Thus, the objective of this study was to identify prognostic factors. MATERIALS AND METHODS: The present study was con ducted with 103 patients who were referred from January 1988 to July 1999. The primary end point was survival. The survival curves were estimated using the Kaplan-Meier method and compared using the Log-rank test and Cox's proportional hazards regression analysis. RESULTS: Most patients had histologic evidence of ade nocarcinoma or squamous cell carcinoma. Univariate and multivariate analyses identified good prognostic factors including performance status (grade 0-2), female and adenocarcinoma with more than moderate level of differentiation. The responders of chemotherapy in squamous cell carcinoma and lung, breast, ovary -estimated- cancer showed good survival rates. CONCLUSION: Unknown primary carcinoma tended to show a poor prognosis. However, when treatment modality of unknown primary carcinoma is to be determined through the prognostic factors, the patients quality of life can be improved through reducing the treatment side effects and economic burden on the patients.
